Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro
Insulin resistance is the inability to respond to insulin and is considered a key pathophysiological factor in the development of type 2 diabetes. Tumor necrosis factor-alpha (TNF-alpha) can directly contribute to insulin resistance by disrupting the insulin signalling pathway via protein-tyrosine p...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2018
|
| In: |
Scandinavian journal of immunology
Year: 2018, Jahrgang: 88, Heft: 5 |
| ISSN: | 1365-3083 |
| DOI: | 10.1111/sji.12716 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/sji.12716
|
| Verfasserangaben: | Lucia A. Méndez-García, Fernanda Trejo-Millán, Camilo P. Martínez-Reyes, Aarón N. Manjarrez-Reyna, Marcela Esquivel-Velázquez, Guillermo Melendez-Mier, Sergio Islas-Andrade, Araceli Rojas-Bernabé, Julia Kzhyshkowska, Galileo Escobedo |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1693493381 | ||
| 003 | DE-627 | ||
| 005 | 20240405193208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200330s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/sji.12716 |2 doi | |
| 035 | |a (DE-627)1693493381 | ||
| 035 | |a (DE-599)KXP1693493381 | ||
| 035 | |a (OCoLC)1341311618 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Méndez-García, Lucia A. |e VerfasserIn |0 (DE-588)1207293350 |0 (DE-627)169349454X |4 aut | |
| 245 | 1 | 0 | |a Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro |c Lucia A. Méndez-García, Fernanda Trejo-Millán, Camilo P. Martínez-Reyes, Aarón N. Manjarrez-Reyna, Marcela Esquivel-Velázquez, Guillermo Melendez-Mier, Sergio Islas-Andrade, Araceli Rojas-Bernabé, Julia Kzhyshkowska, Galileo Escobedo |
| 264 | 1 | |c 2018 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.03.2020 | ||
| 520 | |a Insulin resistance is the inability to respond to insulin and is considered a key pathophysiological factor in the development of type 2 diabetes. Tumor necrosis factor-alpha (TNF-alpha) can directly contribute to insulin resistance by disrupting the insulin signalling pathway via protein-tyrosine phosphatase 1B (PTP1B) activation, especially in adipocytes. Infliximab (Remicade® ) is a TNF-alpha-neutralizing antibody that has not been fully studied in insulin resistance. We investigated the effect of infliximab on TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro, and examined the possible molecular mechanisms involved. Once differentiated, adipocytes were cultured with 5 mmol L-1 2-deoxy-D-glucose-3 H and stimulated twice with 2 μmol L-1 insulin, in the presence or absence of 5 ng/mL TNF-alpha and/or 10 ng/mL infliximab. Glucose uptake was measured every 20 minutes for 2 hour, and phosphorylated forms of insulin receptor (IR), insulin receptor substrate-2 (IRS-2), protein kinase B (AKT) and PTP1B were determined by Western blotting. TNF-alpha-treated adipocytes showed a significant 64% decrease in insulin-stimulated glucose uptake as compared with control cells, whereas infliximab reversed TNF-alpha actions by significantly improving glucose incorporation. Although IR phosphorylation remained unaltered, TNF-alpha was able to increase PTP1B activation and decrease phosphorylation of IRS-2 and AKT. Notably, infliximab restored phosphorylation of IRS-2 and AKT by attenuating PTP1B activation. This work demonstrates for the first time that infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition. Further clinical research is needed to determine the potential benefit of using infliximab for treating insulin resistance in patients. | ||
| 650 | 4 | |a 3T3-L1 Cells | |
| 650 | 4 | |a Adipocytes | |
| 650 | 4 | |a Animals | |
| 650 | 4 | |a Autoinmmunity | |
| 650 | 4 | |a Cytokines | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Enzyme Activation | |
| 650 | 4 | |a Glucose | |
| 650 | 4 | |a In Vitro | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Insulin | |
| 650 | 4 | |a Insulin Resistance | |
| 650 | 4 | |a Mice | |
| 650 | 4 | |a Models, Biological | |
| 650 | 4 | |a Molecules | |
| 650 | 4 | |a Phosphorylation | |
| 650 | 4 | |a Processes | |
| 650 | 4 | |a Protein Tyrosine Phosphatase, Non-Receptor Type 1 | |
| 650 | 4 | |a Signal Transduction | |
| 650 | 4 | |a Subject | |
| 650 | 4 | |a Tumor Necrosis Factor-alpha | |
| 700 | 1 | |a Trejo-Millán, Fernanda |e VerfasserIn |4 aut | |
| 700 | 1 | |a Martínez-Reyes, Camilo P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Manjarrez-Reyna, Aarón N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Esquivel-Velázquez, Marcela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Melendez-Mier, Guillermo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Islas-Andrade, Sergio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rojas-Bernabé, Araceli |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kzhyshkowska, Julia |d 1967- |e VerfasserIn |0 (DE-588)102414271X |0 (DE-627)719213754 |0 (DE-576)368002233 |4 aut | |
| 700 | 1 | |a Escobedo, Galileo |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scandinavian journal of immunology |d Oxford [u.a.] : Wiley-Blackwell, 1972 |g 88(2018,5) Artikel-Nummer e12716, 8 Seiten |h Online-Ressource |w (DE-627)320607623 |w (DE-600)2020954-X |w (DE-576)091170265 |x 1365-3083 |7 nnas |a Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro |
| 773 | 1 | 8 | |g volume:88 |g year:2018 |g number:5 |g extent:8 |a Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro |
| 856 | 4 | 0 | |u https://doi.org/10.1111/sji.12716 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200330 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 102414271X |a Kzhyshkowska, Julia |m 102414271X:Kzhyshkowska, Julia |d 60000 |d 63500 |e 60000PK102414271X |e 63500PK102414271X |k 0/60000/ |k 1/60000/63500/ |p 9 | ||
| 999 | |a KXP-PPN1693493381 |e 3615705823 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1111/sji.12716"],"eki":["1693493381"]},"name":{"displayForm":["Lucia A. Méndez-García, Fernanda Trejo-Millán, Camilo P. Martínez-Reyes, Aarón N. Manjarrez-Reyna, Marcela Esquivel-Velázquez, Guillermo Melendez-Mier, Sergio Islas-Andrade, Araceli Rojas-Bernabé, Julia Kzhyshkowska, Galileo Escobedo"]},"title":[{"title":"Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro","title_sort":"Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"note":["Gesehen am 30.03.2020"],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"2018"}],"relHost":[{"pubHistory":["1.1972 -"],"origin":[{"dateIssuedKey":"1972","dateIssuedDisp":"1972-","publisherPlace":"Oxford [u.a.] ; Oxford ; Oxford [u.a.]","publisher":"Wiley-Blackwell ; Blackwell Science ; Blackwell"}],"note":["Gesehen am 11.04.2022"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"part":{"year":"2018","issue":"5","text":"88(2018,5) Artikel-Nummer e12716, 8 Seiten","volume":"88","extent":"8"},"title":[{"title_sort":"Scandinavian journal of immunology","title":"Scandinavian journal of immunology","subtitle":"the official journal of the Scandinavian Society for Immunology"}],"id":{"zdb":["2020954-X"],"doi":["10.1111/(ISSN)1365-3083"],"eki":["320607623"],"issn":["1365-3083"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"320607623","disp":"Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitroScandinavian journal of immunology"}],"person":[{"family":"Méndez-García","role":"aut","given":"Lucia A.","display":"Méndez-García, Lucia A."},{"given":"Fernanda","role":"aut","family":"Trejo-Millán","display":"Trejo-Millán, Fernanda"},{"family":"Martínez-Reyes","role":"aut","given":"Camilo P.","display":"Martínez-Reyes, Camilo P."},{"display":"Manjarrez-Reyna, Aarón N.","family":"Manjarrez-Reyna","role":"aut","given":"Aarón N."},{"family":"Esquivel-Velázquez","given":"Marcela","role":"aut","display":"Esquivel-Velázquez, Marcela"},{"role":"aut","given":"Guillermo","family":"Melendez-Mier","display":"Melendez-Mier, Guillermo"},{"role":"aut","given":"Sergio","family":"Islas-Andrade","display":"Islas-Andrade, Sergio"},{"display":"Rojas-Bernabé, Araceli","role":"aut","given":"Araceli","family":"Rojas-Bernabé"},{"family":"Kzhyshkowska","given":"Julia","role":"aut","display":"Kzhyshkowska, Julia"},{"display":"Escobedo, Galileo","family":"Escobedo","role":"aut","given":"Galileo"}],"recId":"1693493381","physDesc":[{"extent":"8 S."}]} | ||
| SRT | |a MENDEZGARCINFLIXIMAB2018 | ||